Our team carefully assesses your needs to determine what wellness injections work best for your health
Several principles are worth emphasizing regardless of the specific numbers
As of June 2026, the regulatory picture has three moving parts
Human clinical-trial data (Phase 1/2 studies in wound healing, cardiac injury, and dry eye) exist only for a different, full-length recombinant thymosin beta-4 product, not for the short synthetic fragment marketed as TB-500, so no completed published human trial has evaluated TB-500 specifically for muscle, tendon, or joint recovery
This makes GLOW a strong middle point for research discussions around GHK-Cu, BPC-157 and TB-500 without adding the KPV component found in KLOW
The 0.9% benzyl alcohol preservative inhibits bacterial growth, extending reconstituted shelf life to approximately 30 days